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ABSTRACT
Introduction: Depression is common among children
and adolescents and is associated with significantly
negative effects. A number of structured psychosocial
treatments are administered for depression in children
and adolescents; however, evidence of their effectiveness
is not clear. We describe the protocol of a systematic
review and network meta-analysis to evaluate the efficacy,
quality of life, tolerability and acceptability of the use of
psychological intervention for this young population.
Methods and analysis:We will search PubMed,
EMBASE, CENTRAL (the Cochrane Central Register of
Controlled Trials), Web of Science, PsycINFO, CINAHL,
LiLACS, Dissertation Abstracts, European Association for
Grey Literature Exploitation (EAGLE) and the National
Technical Information Service (NTIS) from inception to
July 2014. There will be no restrictions on language,
publication year or publication type. Only randomised
clinical trials (RCTs) with psychosocial treatments for
depression in children and adolescents will be
considered. The primary outcome of efficacy will be the
mean overall change of the total score in continuous
depression severity scales from baseline to end point.
Data will be independently extracted by two reviewers.
Traditional pairwise meta–analyses will be performed for
studies that directly compared different treatment arms.
Then we will perform a Bayesian network meta–analyses
to compare the relative efficacy, quality of life, tolerability
and acceptability of different psychological intervention.
Subgroup analyses will be performed by the age of
participants and the duration of psychotherapy, and
sensitivity analyses will be conducted to assess the
robustness of the findings.
Ethics and dissemination: No ethical issues are
foreseen. The results will be published in a peer–reviewed
journal and disseminated electronically and in print.
The meta–analysis may be updated to inform and guide
management of depression in children and adolescents.
Trials registration number: PROSPERO
CRD42014010014.
BACKGROUND
Depression is increasing rapidly, and ranks
fourth on the list of disorders with the highest
burden of disease worldwide.1 The point
prevalence of depression has been estimated to
be approximately 2% in children (6–12 years)
and 2–8% in adolescents (13–18 years), with a
peak incidence around puberty.2 3 The average
duration of a depressive episode in children
and adolescents is about 9 months.4 However,
70% of patients whose symptoms remit develop
subsequent depressive episodes within 5 years,
and research also shows continuity between
childhood depression and depression experi-
enced in adulthood.4 5 Compared with diagno-
sis of adults, diagnoses of depressed children
and adolescents are more often missed5 and
have more frequent suicide attempts and
thoughts, particularly in teenage girls.6 There
is also serious impairment in social function-
ing, including poor school achievement and
relational problems with family members and
peers.7 8
In the past two decades, the availability of
effective treatments for depression in chil-
dren and adolescents has increased, with two
broad categories of treatment being used to
treat this population: psychotherapy and
pharmacotherapy (eg, tricyclic antidepres-
sants (TCAs) and serotonin selective reuptake
inhibitors (SSRIs)).9 10 In the management
of mild to moderate depression, the first
Strengths and limitations of this study
▪ This Bayesian network meta-analysis can inte-
grate direct evidence with indirect evidence from
multiple treatment comparisons to estimate the
interrelations across all treatments.
▪ We will comprehensively assess the efficacy,
quality of life, tolerability, acceptability and suicide-
related outcomes in acute treatment and follow-up.
▪ A series of subgroup and sensitivity analyses will
address clinically relevant questions.
▪ This study should help guide clinical decision-
making of psychotherapeutic interventions to
better treat child and adolescent depression.
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treatment option is still psychotherapy no matter which
method is used.10 11 In the USA, approximately three
quarters of children and adolescents treated for depres-
sion are reported to have received some form of psycho-
therapy, although approximately one-third of patients
underwent only one or two treatment visits during the
course of the survey year.12 For pharmacotherapy, TCAs
are unlikely to benefit children and adolescents with
depression,13 and treatment with SSRIs has been contro-
versial because of evidence of a significant increase in the
risk of suicidality compared to a placebo.14 15 Thus, con-
cerns about this issue have refocused attention on the
prevalence of depression in young patients, particularly
on the most prominent medication alternative, psycho-
therapy and on the question of how effective this treat-
ment is with youth depression.16
The aim of psychotherapy is to build a relationship
with the client through a structured and purposeful
encounter, and although a range of specific techniques
are employed, life issues and problems can be discussed
and addressed. Just as there are many approaches to psy-
chological therapies, the assumed mechanism of action
for each varies. However, common to most is the aim to
increase awareness, with the implicit or explicit aim of
changing thoughts, behaviours or emotions to improve
the mental health and well-being of the client.17 In clin-
ical practice, depressed children and adolescents are
more likely to show an irritable mood, rather than the
sad mood that features in depressed adults,9 and dra-
matic brain changes have been found between childhood
and adult patients in previous studies.18 19 Therefore, it is
important to analyse psychotherapy use in children and
adolescents separately from adults. Since the late 1990s,
several rigorous studies have been conducted validating
the efficacy of psychotherapeutic approaches in child
and adolescent depression.20–22 Currently, a number of
structured psychosocial treatments are administered for
depression in children and adolescents, such as cognitive-
behavioural therapy (CBT), which has also been com-
monly used for adult patients.23 Other types of psy-
chotherapies include behavioural, cognitive,
interpersonal, problem-solving, play, psychodynamic and
family. So far, there have been only a few systematic
reviews or meta-analyses for depression in children and
adolescents, and the evidence of effectiveness of psycho-
therapy remains unclear.16 24–27 One recent meta-analysis
by Cox et al17 found that the existing evidence is not suffi-
cient to robustly determine the relative effectiveness of
antidepressants and psychological therapies (alone or in
combination) for treating depression in children and
adolescents, and another meta-analysis showed a modest
benefit from antidepressants with no additional benefit
over medication from CBT for treatment-resistant depres-
sion in adolescents.26 In addition, Hetrick et al’s27 study
found that the efficacy of psychotherapy varies with differ-
ent therapeutic components (eg, behavioural therapy
may lead to better treatment outcomes in young
people).27 However, these systematic reviews and
meta-analyses have not focused on any head-to-head com-
parisons of different psychological interventions. Thus,
the evidence of hierarchies for the efficacy and tolerabil-
ity of these interventions in acute phase treatment and
follow-up has never been assessed in the comprehensive
setting of a systematic review and meta-analysis.
For these reasons, a better-designed approach utilising
Bayesian network meta-analysis is urgently needed in this
area, integrating direct evidence (from studies directly
comparing interventions) with indirect evidence (infor-
mation about two treatments derived via a common com-
parator) from multiple treatment comparisons to
estimate the interrelations across all treatments.28 This
approach enables a coherent analysis of random trials
data for comparisons of multiple treatments without
adversely affecting randomisation of treatments within
each trial, and its usefulness has been previously demon-
strated in several studies on various medical conditions
and interventions, such as antidepressants or psychother-
apy for depression in adults,29 30 and antimanic drugs for
mania in adults.31 Recently, we have completed a network
meta-analysis comparing first-generation and second-
generation antidepressants for depression in children,
adolescents and young adults. To further improve the
management for depression in children and adolescents,
we will conduct a systematic review and network meta-
analysis to evaluate the efficacy, quality of life, tolerability
and acceptability of the use of psychological intervention
for this young population.
METHODS
Criteria for included studies
Types of studies
Any relevant randomised controlled trials (RCTs) will be
included. Quasi-randomised trials (such as those allocat-
ing by using alternate days of the week) will be
excluded. For trials that have a crossover design, only
the results from the first randomisation period will be
considered. Also, the cluster RCTs will be included.
Types of participants
Children or adolescents should be between the ages of 6
and 18 years when they initially participated in the
primary studies. For the purpose of reducing clinical
heterogeneity, investigators always use one strict diagnos-
tic definition, such as Diagnostic and Statistical Manual
of Mental Disorders, fourth edition (DSM-IV) or
International Classification of Diseases 10th revision
(ICD-10), to diagnose major depression. However, it is
most likely that this method could overlook a lot of
important information from clinical settings, because
some children and adolescents, who do not satisfy the
typical criteria of major depression but suffer from
depressive symptoms or subthreshold depression, can
also have serious functional deterioration in social and
educational situations. Therefore, the following broad
criteria to identify the participants will be applied in our
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study:(1) major depression as diagnosed according to
standardised criteria such as DSM-III,32 DSM-III-R,33
DSM-IV,34 ICD-9,35 ICD-10,36 Research Diagnostic
Criteria37 and Feighner criteria,38 (2) minor or intermit-
tent depression, or dysthymia as diagnosed according to
standardised criteria such as DSM-III, DSM-III-R, DSM-IV,
ICD-9, ICD-10, Research Diagnostic Criteria and
Feighner criteria, (3) depressive status, defined as scoring
above a certain cut-off on a depression rating scale
according to the original authors’ definition, such as the
Hamilton Rating Scale for Depression (HRSD),39
Children’s Depression Inventory (CDI),40 Beck depres-
sion inventory (BDI),41 Center for Epidemiologic Study
Depression Scale(CES-D),42 Children’s Depression
Rating Scale (CDRS)43 or Children’s Depression Rating
Scale-Revised (CDRS-R).44 Trials where adults and
children or adolescents are treated will be eligible for
inclusion, if data on the children or adolescents could be
extracted separately or obtained from trial authors. The
studies where participants had comorbid secondary
medical or other mental health conditions, including
comorbid with suicidal ideation/attempt will not be
excluded; however, participants with a secondary diagno-
sis of Axis I psychiatric disorders (eg, schizophrenia and
bipolar disorder) will be excluded because the effective-
ness of psychotherapy might be affected by these
comorbidities. Besides, studies in which participants have
a diagnosis of resistant depression or psychotic depres-
sion will be excluded.
Types of interventions
RCTs comparing one psychological intervention with
another or either of the control conditions for depres-
sion in children and adolescents will be included. For
psychotherapy, CBT, behavioural therapy (BT), cognitive
therapy (CT), interpersonal therapy, problem-solving
therapy, play therapy, supportive counselling, psycho-
dynamic therapy and family therapy will be included
regardless of their treatment session and duration. The
psychotherapy will be shown in table 1. We will view
these psychological interventions as independent nodes
in this network meta-analysis regardless of the treatment
medium (face-to-face, website, telephone or other).
If sufficient numbers of studies compared between dif-
ferent treatments in the same type of psychotherapy as
currently described are detected, we will consider
viewing it as another new node because it seems that the
effect of each type of psychotherapy is unique.
In terms of control conditions, waiting-list control
(WL), non-treatment control, treatment as usual (TAU)
and (psychological or pill) placebo will be included.
TAU is not considered to be psychotherapy but may
have some treatment effects. Placebo may also have
some potential treatment effects, whereas non-treatment
and WL do not have any active treatment effects.
Therefore, we will also view these control conditions as
independent nodes in this network meta-analysis, except
that the non-treatment and waiting list will be regarded
as one node. Regular reviews of mental health symptoms
and interventions, such as psychodrama and art exercise,
will be regarded as psychological placebos because they
involve time spent with the patient but without a focus
on improving depressive symptoms.24
Trials in which psychotherapy is used as a combination
strategy (such as combining different psychological
interventions or psychotherapy and antidepressants) will
be excluded, while studies with concomitant use of an
auxiliary psychotropic agent (eg, benzodiazepine for
insomnia) will be included.
Types of outcome measures
Acute phase treatment
We will assess the effects of acute phase treatment post-
treatment in order to examine the possible maximum
effects of psychotherapy.
Overall efficacy
1. The primary outcome of efficacy will mean overall
change in the total score in continuous depression
severity scales from baseline to end point, which will
be assessed in the first instance by change in HRDS.
If data are not available, we will use change in BDI or
CDI and then other depressive rating scales.
2. Secondary outcome of efficacy will be the proportion
of patients who respond to treatment, which is
defined as substantial overall improvement from base-
line as defined by the original investigators, such as
more than a 50% reduction on a depression continu-
ous measure (ie, ‘1=very much improved’ or
‘2=Much improved’ according to the Clinical Global
Improvement (CGI) Scale or other criteria).42 When
‘response’ is not reported, we will use ‘remission’ if
available. Remission is defined as a reduction to the
normal range (such as HRSD score ≤9, BDI score
≤10, CDI ≤12) and variably across studies.45
Overall acceptability
All-cause discontinuation as a proxy measure of treat-
ment acceptability is defined as the proportion of
patients who drop out for any reason.
Overall tolerability
Side effects discontinuation as a measure of treatment
tolerability is defined as the proportion of patients who
drop out for any reason.
Quality of life/functioning improvement
Quality of life/functioning improvement (QoL/func-
tioning) means overall change in the total score in con-
tinuous quality of life scales from baseline to end point,
for example, Quality of Life Enjoyment and Satisfaction
Questionnaire (Q-LES-Q)46 and the Short Form 36
Health Survey (SF-36),47 etc, or functioning improve-
ment scales, for example, Sheehan Disability Scale
(SDS).48 As measures of QoL/functioning vary across
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studies, we will pool such measures together to create an
omnibus effect size for each psychotherapy.
Suicide-related outcomes
We consider suicide-related outcomes as both a dichot-
omous and continuous outcome. If data are available,
we will extract the number of participants with suicidal
behaviour/ideation during the acute treatment, as mea-
sured on a standardised, validated and reliable rating
scale such as the Suicidal Ideation Questionnaire-Junior
High School version.49 In addition, we will also collect
data on suicidal ideation as a continuous outcome
where a standardised, validated and reliable rating scale
has been used.
Follow-up measure
After the acute phase treatment, we will assess the effects
at the end of follow-up (maximum of up to 12 months)
in order to examine the possible delayed or mainten-
ance effects of psychotherapy. If some participants took
further treatments, including continuous treatment,
booster sessions or any other psychotherapies or antide-
pressants during the follow-up period, we will exclude
them in the follow-up analysis. Therefore, the number
of participants who did not take further treatments will
be used as a measure of follow-up efficacy of the acute
phase interventions. Owing to the variability in follow-up
points, and the fact that some studies assessed outcomes
at multiple follow-up time points, we will collect data at
the last time points as an outcome measure.
Overall efficacy
1. The primary outcome of efficacy in the long term
will be defined as the mean overall change in con-
tinuous depression severity scales, which is similar to
the acute phase treatment measurement.
2. The secondary outcome of efficacy will be defined as
‘response’, which is similar to the acute phase treat-
ment measurement.
Overall acceptability
All-cause discontinuation as a proxy measure of treat-
ment acceptability is defined as the proportion of
patients who drop out for any reason.
Overall tolerability
Side effects discontinuation as a measure of treatment
tolerability is defined as the proportion of patients who
drop out for any reason.
Quality of life/functioning improvement
QoL/functioning will be the mean overall change in
continuous quality of life scales or functioning improve-
ment scales, which is similar to the acute phase treat-
ment measurement.
Suicide-related outcomes
We consider suicide-related outcomes as both a dichot-
omous and continuous outcome. If data are available,
we will extract the number of participants with suicidal
behaviour/ideation during the acute treatment, as mea-
sured on a standardised, validated and reliable rating
Table 1 Description of intervention strategies
Psychological
intervention Abbreviation Description
Cognitive behavioural
therapy
CBT CBT uses some kind of cognitive restructuring training and promotes behavioural
change
Behavioural therapy BT It uses some kind of behavioural training and thus promotes cognitive change. It
may include relaxation therapy, biofeedback, coping skills, behavioural activation
or social skills training
Cognitive therapy CT It uses some kind of cognitive restructuring training but does not promote
behavioural change
Interpersonal therapy IPT IPT is a brief and highly-structured manual-based psychotherapy that focuses on
the participants’ social relationships and current evaluation of these relationships
Problem-solving therapy PST PST focuses on the problems participants currently face and on helping them find
solutions to these problems
Play therapy – It uses techniques to engage participants in recreational activities to help them
cope with their problems and fears
Non-directive supportive
therapy
SUP SUP is an unstructured therapy without specific psychological techniques that
helps people to express their experiences and emotions and offer empathy.
These nondirective therapies are commonly described in the literature as either
counselling or supportive therapy
Psychodynamic therapy DYN DYN refers to a technique designed to help a person understand the origin and
nature of long-standing problems, including psychological trauma
Family therapy – It works with families and couples in intimate relationships to nurture change and
development. It tends to view change in terms of the systems of interaction
between family members
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scale such as the Suicidal Ideation Questionnaire-Junior
High School version.49 In addition, we will also collect
data on suicidal ideation as a continuous outcome
where a standardised, validated and reliable rating scale
has been used.
Search strategy
All published, unpublished and ongoing RCTs that com-
pared one psychological intervention with another or
either of the control conditions in the treatment of
depression in children and adolescents will be identified.
We will identify relevant trials from systematic searches in
the following electronic databases: MEDLINE/PubMed,
EMBASE, CENTRAL (the Cochrane Central Register of
Controlled Trials), Web of Science, PsycINFO, CINAHL
and LiLACS. A comprehensive search of unpublished
theses and dissertations via ProQuest Dissertation
Abstracts, European Association for Grey Literature
Exploitation (EAGLE) and National Technical
Information Service (NTIS) will be completed. We will
search clinicaltrials.gov for ongoing trial registers. We will
also check relevant reports on the US Food and Drug
Administration (FDA) website, the WHO’s trial portal,
and hand-search major psychiatric and medical journals.
The search deadline will be from inception up to July
2013. No language restrictions will be applied. Details of
search strategies can be found in online supplementary
appendix table 1. Electronic databases will be searched
using the following strategy: additional relevant studies
will be obtained by scanning reference lists of trials iden-
tified in the initial searches and relevant review papers.
In addition, all relevant authors will be contacted to sup-
plement incomplete information.
Study selection and data extraction
Selection of trials
Titles and abstracts of references identified by the elec-
tronic search strategies described above will be inde-
pendently examined by two reviewers (BQ and YL).
If both reviewers judge that the trial does not meet eligi-
bility criteria, we will exclude it. Then we will obtain the
full texts of all remaining articles and determine
whether to include them by the same eligibility criteria.
The inter-rater reliability of the two raters will be calcu-
lated. Besides, the references of relevant review papers
and included trials will be checked by BQ and YZ. Any
disagreement will be resolved by consensus between the
two reviewers and, if need be, with another reviewer
(XZ). The reasons for exclusion of trials will be reported
in the characteristics of excluded studies tables.
Quality assessment
Two reviewers (BQ and YL) will independently assess the
methodological quality of the included studies. We will
assess risk of bias as ‘low risk’, ‘unclear risk’ or ‘high
risk’, in accordance with The Cochrane Collaboration’s ‘
Risk of bias’ tool as described in the Cochrane
Handbook for Systematic Reviews of Interventions.50
The following items will be assessed:
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants, personnel and outcome
assessors (assessments should be made for each main
outcome or class of outcomes).
4. Incomplete outcome data (assessments should be
made for each main outcome or class of outcomes).
5. Selective outcome reporting.
6. Other sources of bias.
The inter-rater reliability of the total score of study
quality assessment will be examined. Any disagreement
will be resolved by consensus between the two raters
and, if need be, with another reviewer (XZ).
Data extraction
Two independent reviewers (BQ and YL) will extract the
data from the original reports using standardised data
extraction forms, which include f study characteristics
(such as first listed author, publication year, journal,
country, institution and sponsor), patient characteristics
(such as diagnostic criteria for depression, the type of
patients, the number of patients and patients’ baseline),
intervention details (such as psychotherapy type, session
of psychotherapy, the duration of treatment, treatment
setting and pattern) and outcome measures (such as the
patients of intention-to-treat (ITT) analysis, acute treat-
ment outcomes and follow-up outcomes). Any disagree-
ments will be resolved by a third review author (XZ).
Statistical analysis
First, traditional pairwise meta-analyses will be per-
formed for studies that directly compared different treat-
ment arms. Then we will perform a Bayesian network
meta-analysis to assess the relative outcomes of different
psychotherapies and control conditions with each other
from all direct and indirect comparisons. Dichotomous
outcomes will be analysed on an ITT basis: dropouts will
always be included in this analysis. When data on drop-
outs are carried forward and included in the evaluation
(Last Observation Carried Forward, LOCF), they will be
analysed according to the primary studies. Scores from
continuous outcomes will not be analysed on an ITT
basis. Continuous outcomes will therefore be analysed
on an end point basis, including only participants with a
final assessment or with a LOCF to the final assessment.
Traditional pairwise meta-analyses
Traditional pairwise meta-analyses will be performed
using Review Manager (V.5.2). Using the DerSimonian
method and the Laird random-effects model, the
pooled estimates of standardised mean difference
(SMD) with 95% CIs will be calculated for the continu-
ous outcomes, and ORs with 95% CIs will be calculated
for the dichotomous outcomes. Heterogeneity of treat-
ment effects across studies will be assessed by I2 and the
Q-statistic test.50
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Bayesian network meta-analyses
Network meta-analyses will be performed using the
WinBUGS software package (V.1.4.3, MRC Biostatistics
Unit, Cambridge, UK) with random-effects models for mul-
tiarm trials.28 51 The other analyses will be performed and
presented by the Stata V.11.0 and R V.2.11.1 software
packages. Network meta-analyses will be performed on two
different evidence networks. The primary analysis is based
on a network where the psychological interventions men-
tioned above will be treated as a separate node regardless
of group or individual treatment. A secondary evidence
network of drug class will also be constructed to view the
group psychotherapy or individual psychotherapy in the
same intervention as a separate node. The pooled esti-
mates will be obtained using the Markov Chains Monte
Carlo method. Two Markov chains will be run simultan-
eously with different arbitrarily chosen initial values. To
ensure convergence, trace plots and the Brooks-Gelman-
Rubin statistic will be assessed.52 Convergence will be
found to be adequate after running 50 000 samples for
both chains. These samples will then be discarded as
‘burn-in,’ and posterior summaries will be based on
100 000 subsequent simulations. All results will be reported
as posterior medians of SMD or with corresponding 95%
credible intervals (CrIs), which can be interpreted like con-
ventional 95% CIs. When a loop connected three treat-
ments, it was possible to evaluate the inconsistency between
direct and indirect evidence. The node splitting method
will be used to calculate the inconsistency of the model,
which separates evidence on a particular comparison into
direct and indirect evidence.53
The probability of each treatment being the most
effective (best, second-best, third-best and so on) will be
calculated and graphically ranked with rankograms.54
Probability values will be summarised and reported as
surface under the cumulative ranking curve (SUCRA), a
simple transformation of the mean rank used to provide
a hierarchy of the treatments that accounts for the loca-
tion and the variance of all relative treatment effects.55
The larger the SUCRA value, the better the rank of the
treatment with a SUCRA of 1.0 if an intervention always
ranks first and 0.0 if it always ranks last.
Subgroup analysis
Where possible, we will perform the following subgroups
analysis: (1) for the age of participants (eg, children
aged 6–12 years or adolescents from 13 to 18 years); and
(2) for the duration of psychotherapy (eg, short-term
treatment of six or fewer weeks or long-term treatment
of more than 6 weeks).
Sensitivity analyses
We will perform the following sensitivity analyses: (1) by
limiting the studies to be included to those of higher
quality; (2) by limiting studies to those that employed
standardised criteria for major depression; (3) by
excluding studies with comorbid physical or mental dis-
orders that were not a primary diagnosis (if possible,
excluding only participants who had a comorbid diagno-
sis); (4) by excluding studies with a concomitant use of
psychotropic agents (if possible, excluding only partici-
pants who had a concomitant use of psychotropic
agents); (5) by excluding studies with small sample sized
trials; and (6) by excluding studies with mild and inter-
mittent depression patients.
Funnel plot analysis and meta-regression analysis
We will perform funnel plot analyses to check for publi-
cation bias. Moreover, we will carry out meta-regression
analyses to investigate the effect of sponsorship or year
published on outcome estimate.
Ethics and dissemination
This systematic review and network meta-analysis will be
published in a peer–reviewed journal. It will be dissemi-
nated electronically and in print. As no primary data col-
lection will be undertaken, no additional formal ethical
assessment and informed consent are required.
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